Clinical trial outcomes of adults with HGBL, NOS
| Study . | Treatment . | Study population* . | HGBL, NOS, n . | PFS, % (y)† . | OS, % (y)† . |
|---|---|---|---|---|---|
| Cook et al, 61 | R-CHOP ± ASCT | DLBCL or HGBL | 31 | 69 (2) | 77 (2) |
| Persky et al, 71 | R-CHOP ± IFRT/IbT | Localized DLBL or HGBL | 22 | 87 (5)‡ | 89 (5)‡ |
| Mead et al, 76 | CODOX-M/IVAC | BL or DLBCL with Ki-67 >95% | NR (DLBCL, 57) | 55 (2) | 59 (2) |
| Corazzelli et al, 77 | R-CODOX-M/IVAC | BL or HGBL | 15 | 65 (4) | NR |
| McMillan et al, 82 | R-CODOX-M/IVAC | DLBCL with IPI 3-5 | NR | 68 (2) | 76 (2) |
| Dunleavy et al, 63 | DA-EPOCH-R | DLBCL with MYC-R | 10 | 71 (4) | 77 (4) |
| Hoelzer et al, 85 | GMALL-B-ALL/NHL2002 | BL, HGBL, Burkitt leukemia | NR | 75 (5)‡ | 80 (5)‡ |
| Thomas et al, 91 | R-hyperCVAD/MA | BL, HGBL, B-ALL | 16 | 80 (3)‡ | 89 (3)‡ |
| Rizzieri et al, 90 | CALGB 10002 | BL or HGBL | 25 | 64 (2) | 64 (2) |
| Study . | Treatment . | Study population* . | HGBL, NOS, n . | PFS, % (y)† . | OS, % (y)† . |
|---|---|---|---|---|---|
| Cook et al, 61 | R-CHOP ± ASCT | DLBCL or HGBL | 31 | 69 (2) | 77 (2) |
| Persky et al, 71 | R-CHOP ± IFRT/IbT | Localized DLBL or HGBL | 22 | 87 (5)‡ | 89 (5)‡ |
| Mead et al, 76 | CODOX-M/IVAC | BL or DLBCL with Ki-67 >95% | NR (DLBCL, 57) | 55 (2) | 59 (2) |
| Corazzelli et al, 77 | R-CODOX-M/IVAC | BL or HGBL | 15 | 65 (4) | NR |
| McMillan et al, 82 | R-CODOX-M/IVAC | DLBCL with IPI 3-5 | NR | 68 (2) | 76 (2) |
| Dunleavy et al, 63 | DA-EPOCH-R | DLBCL with MYC-R | 10 | 71 (4) | 77 (4) |
| Hoelzer et al, 85 | GMALL-B-ALL/NHL2002 | BL, HGBL, Burkitt leukemia | NR | 75 (5)‡ | 80 (5)‡ |
| Thomas et al, 91 | R-hyperCVAD/MA | BL, HGBL, B-ALL | 16 | 80 (3)‡ | 89 (3)‡ |
| Rizzieri et al, 90 | CALGB 10002 | BL or HGBL | 25 | 64 (2) | 64 (2) |
ASCT, autologous stem cell transplantation; B-ALL, B-cell acute lymphoblastic leukemia; CALGB, Cancer and Leukemia Group B; GMALL, German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia; IFRT/IbT, involved-field radiation therapy followed by ibritumomab tiuxetan consolidation; NR, not reported; R-hyperCVAD/MA, rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine.
In this table, the term HGBL encompasses Burkitt-like lymphoma, BCLU, DHL, and HGBL, NOS.
Outcomes of the HGBL subset, unless stated otherwise.
Outcomes in the entire study population (results reportedly did not significantly differ for HGBL).